MedTrace Logo

Effect of ATI-7505 on Gastrointestinal Transit in Healthy Volunteers

NCT01094821 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2010-03-29

No results posted yet for this study

Summary

This is a pharmacodynamic study in healthy volunteers to determine the effects of a new 5-HT4 agonist on gastric, small bowel and colonic transit.

Conditions

  • Healthy

Interventions

DRUG

ATI-7505

3 mg three times daily for 9 days

DRUG

Placebo

Placebo capsule three times daily for 9 days

DRUG

ATI-7505

10 mg ATI-7505 three times daily for 9 days

DRUG

ATI-7505

20 mg ATI-7505 three times daily for 9 days

Sponsors & Collaborators

  • ARYx Therapeutics

    collaborator INDUSTRY

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Michael Camilleri, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2005-12-31
Completion
2005-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01094821 on ClinicalTrials.gov